Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tuna Mutis

Showing results (71-80 of 110) with videos related to

Pageof 11
Sort By:
Hemasphere|July 14, 2025
Surface downmodulation of TIM3 safeguards healthy cells but not acute myeloid leukemia from CAR T-cell therapyJort J van der Schans, Paresh Vishwasrao, Renée Poels, et al.
Blood|June 22, 2011
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 TrialEvelien Kneppers, Bronno van der Holt, Marie-Jose Kersten, et al.
Cell Reports|May 24, 2016
RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell ReceptorZsolt Sebestyen, Wouter Scheper, Anna Vyborova, et al.
Journal for Immunotherapy of Cancer|July 26, 2024
Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myelomaCharlotte L B M Korst, Chloe O'Neill, Wassilis S C Bruins, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 15, 2014
Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopesRieuwert Hoppes, Rimke Oostvogels, Jolien J Luimstra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2021
Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of ApoptosisLisa C Holthof, Jort J van der Schans, Afroditi Katsarou, et al.
Expert Review of Clinical Immunology|February 22, 2018
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experienceKristine A Frerichs, Noemi Anna Nagy, Pieter L Lindenbergh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2013
Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistanceSanne J de Haart, Niels W C J van de Donk, Monique C Minnema, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2024
T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple MyelomaChristie P M Verkleij, Chloe A O'Neill, Marloes E C Broekmans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2014
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and BortezomibInger S Nijhof, Richard W J Groen, Willy A Noort, et al.
Pageof 11

Showing results (71-80 of 110) with videos related to

Sort By:
Pageof 11
Hemasphere|July 14, 2025
Surface downmodulation of TIM3 safeguards healthy cells but not acute myeloid leukemia from CAR T-cell therapyJort J van der Schans, Paresh Vishwasrao, Renée Poels, et al.
Blood|June 22, 2011
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 TrialEvelien Kneppers, Bronno van der Holt, Marie-Jose Kersten, et al.
Cell Reports|May 24, 2016
RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell ReceptorZsolt Sebestyen, Wouter Scheper, Anna Vyborova, et al.
Journal for Immunotherapy of Cancer|July 26, 2024
Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myelomaCharlotte L B M Korst, Chloe O'Neill, Wassilis S C Bruins, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 15, 2014
Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopesRieuwert Hoppes, Rimke Oostvogels, Jolien J Luimstra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2021
Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of ApoptosisLisa C Holthof, Jort J van der Schans, Afroditi Katsarou, et al.
Expert Review of Clinical Immunology|February 22, 2018
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experienceKristine A Frerichs, Noemi Anna Nagy, Pieter L Lindenbergh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2013
Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistanceSanne J de Haart, Niels W C J van de Donk, Monique C Minnema, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2024
T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple MyelomaChristie P M Verkleij, Chloe A O'Neill, Marloes E C Broekmans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2014
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and BortezomibInger S Nijhof, Richard W J Groen, Willy A Noort, et al.
Pageof 11